HippoFi, Zimmer Biomet, partner for spine biologics

Biologics

HippoFi and Zimmer Biomet are partnering to develop and launch a novel synthetic biomaterial for bone growth.

HippoFi and its subsidiary PUR Biologics have FDA 510(k) clearance for ActiveOrb technology and a global license from Zimmer Biomet to use in the spine market, according to a Sept. 7 news release. The companies are working under a joint commercialization research agreement to produce spine-specific products.

The synthetic biomaterial is expected to launch in 2024.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like

 

Featured Webinars

Featured Whitepapers